History, Evolution, and Milestones in Cancer Research and Treatment
Author:
Publisher
Springer Nature Singapore
Link
https://link.springer.com/content/pdf/10.1007/978-981-99-6263-1_2
Reference126 articles.
1. Alverson DC, Krupinski EA, Erps KA, Rowe NS, Weinstein RS (2019) The third national telemedicine & telehealth service provider showcase conference. Telemed J E Health 25(4):332–340. https://doi.org/10.1089/tmj.2018.0096
2. American Cancer Society. www.cancer.org | 1.800.227.2345
3. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N et al (2014) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20(17):4436–4441. https://doi.org/10.1158/1078-0432.CCR-14-0012
4. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway, CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, & REDUCE Study Group (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202. https://doi.org/10.1056/NEJMoa0908127
5. Azike JE (2009) A review of the history, epidemiology and treatment of squamous cell carcinoma of the scrotum. Rare Tumors 1(1):47–49
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3